Remedy Robotics Raises $62 Million Series B to Advance N1 System Clinical Development

Written by

in

Remedy Robotics has completed a $62 million Series B financing to advance the N1 System’s critical clinical trials, FDA approval process, and prototype deployments. The company is developing a machine learning-powered neurovascular interventional robotics platform and software suite that can analyze preoperative images, perform preoperative simulations and real-time 3D-2D registration, and support robotic procedures. Remedy currently collaborates with more than 100 hospitals worldwide, but the N1 System remains under development and has not yet been approved for sale or clinical use in any jurisdiction.

Source:Stay Updated With Medical Buyer · Read original

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *